Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)

Abstract Even though pulmonary arterial hypertension (PAH) remains an incurable disease, the combination of PAH‐specific therapies allowed treatment strategies to evolve from symptom‐based ones to others that aim to move patients to low‐risk conditions. Endothelin‐1 (ET‐1) receptor antagonists emerg...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Abdullah M. Aldalaan, Sarfraz A. Saleemi, Ihab Weheba, Abeer Abdelsayed, Maha M. Aleid, Fatima Alzubi, Hamdeia Zaytoun, Nadeen Alharbi
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2022-04-01
Schriftenreihe:	Pulmonary Circulation
Schlagworte:	Bosentan efficacy Macitentan pulmonary arterial hypertension safety switch
Online-Zugang:	https://doi.org/10.1002/pul2.12083
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!